Loading…
Upstream Bio, Inc. is projected to rise to $8.58 by 2027, a +4% move from its current price of $8.26. UPB is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $8.01 | $8.26 | $8.51 | -0.02% |
| May 30 | $7.91 | $8.26 | $8.62 | -0.04% |
| May 31 | $7.83 | $8.25 | $8.70 | -0.06% |
| Jun 1 | $7.77 | $8.25 | $8.77 | -0.09% |
| Jun 2 | $7.71 | $8.25 | $8.83 | -0.11% |
| Jun 3 | $7.66 | $8.25 | $8.89 | -0.13% |
| Jun 4 | $7.61 | $8.25 | $8.94 | -0.15% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $7.61 | $8.25 | $8.94 | -0.15% |
| Week 2 | $7.35 | $8.24 | $9.22 | -0.30% |
| Week 3 | $7.16 | $8.22 | $9.45 | -0.45% |
| Week 4 | $6.99 | $8.21 | $9.64 | -0.60% |
| Week 5 | $6.85 | $8.20 | $9.81 | -0.75% |
| Week 6 | $6.72 | $8.19 | $9.96 | -0.90% |
| Week 7 | $6.61 | $8.17 | $10.11 | -1.05% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Upstream Bio, Inc. is a clinical-stage biotechnology company that develops treatments for inflammatory diseases, focusing on severe respiratory disorders.
It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease.
The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.
UPB trades at $8.37 and has a market capitalization of $455.5M. It is currently ranked 3108 by market cap.
The 2026 forecast shows a neutral stance with a min of $7.36, an average of $8.37, and a max of $11.02, implying an ROI of 0%. This year is labeled NEUTRAL in sentiment.
From 2032 onward the forecast turns bullish, with a 2032 average price of $10.47 and a max of $16.53. The long-run path includes 2040 with an average of $17.04 and a max of $30.38, and 2050 with an average of $25.76 and a max of $50.72, with ROIs of 25.1%, 103.5%, and 207.8% respectively.
Overall, the path suggests meaningful upside over the horizon, though the near term remains restrained and volatility is high given the projected ranges.
A major floor 18.6% below — a decisive break under it would weaken the trend.
Price is testing support right now (2.8% away) — a key level to hold.
The nearest ceiling, 22.3% above — a clean break opens room to run.
A major ceiling 293.5% above — clearing it would confirm fresh momentum.
Key UPB support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of UPB market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $8.34 | Sell | $8.34 | Sell |
| MA 10 | $8.55 | Sell | $8.51 | Sell |
| MA 20 | $8.85 | Sell | $8.78 | Sell |
| MA 50 | $9.22 | Sell | $10.06 | Sell |
| MA 100 | $14.61 | Sell | $12.92 | Sell |
| MA 200 | $18.44 | Sell | $15.30 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 38.88 | Neutral |
| Stoch RSI (14) | 35.50 | Neutral |
| CCI (20) | -104.58 | Sell |
| Williams %R (14) | -82.71 | Info |
| MACD (12,26,9) | -0.04 | Sell |
| ROC (12) | -9.13 | Sell |
| Bollinger %B (20,2) | 0.15 | Neutral |
| Stochastic %K (14) | 17.29 | Buy |
| TRIX (15) | -0.43 | Sell |
| Awesome (5,34) | -0.92 | Sell |
| Ultimate (7,14,28) | 30.92 | Neutral |
| Momentum (10) | -0.69 | Sell |
| Aroon Osc (25) | -76.00 | Sell |
| Hull MA (9) | 8.23 | Buy |
| ADX (14) | 18.06 | Neutral |
| ATR (14) | 0.25 | Info |
The 30-day technical picture is Bearish.
RSI(14) is 40, and the trend is below the SMA50 at $9.27 while far below the SMA200 at $18.52, signaling downside risk relative to the longer-term trend.
Key support sits at $8.03 and resistance at $10.34, with the 30-day price range spanning $6.78 to $10.34. Annualized volatility stands around 60%, underscoring sizable near-term fluctuations.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $7.36 | $8.26 | $10.83 | 0% | Neutral | |
| $6.73 | $8.58 | $11.63 | +4% | Neutral | |
| $6.72 | $8.83 | $12.44 | +7% | Neutral | |
| $6.07 | $8.18 | $11.89 | -1% | Neutral | |
| $6.22 | $8.58 | $12.80 | +4% | Neutral | |
| $6.79 | $9.57 | $14.60 | +16% | Neutral | |
| $7.38 | $10.59 | $16.49 | +28% | Bullish | |
| $8.08 | $11.82 | $18.75 | +43% | Bullish | |
| $8.23 | $12.25 | $19.77 | +48% | Bullish | |
| $8.20 | $12.42 | $20.35 | +50% | Bullish | |
| $10.48 | $17.14 | $30.00 | +107% | Bullish | |
| $14.05 | $26.28 | $50.63 | +218% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $7.36 | $8.26 | $9.67 | +0.00% |
| June 2026 | $6.79 | $7.99 | $9.65 | -3.23% |
| July 2026 | $6.82 | $8.10 | $9.92 | +1.32% |
| August 2026 | $6.80 | $8.15 | $10.09 | +0.58% |
| September 2026 | $6.58 | $7.92 | $9.91 | -2.73% |
| October 2026 | $6.59 | $7.98 | $10.06 | +0.68% |
| November 2026 | $6.86 | $8.35 | $10.61 | +4.68% |
| December 2026 | $6.92 | $8.47 | $10.83 | +1.37% |
Click any year to see its month-by-month UPB forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect UPB to range from $7.36 to $10.83 through 2026. The $8.26 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The UPB price prediction for 2027 points to an average of $8.58 (low $6.73, high $11.63) — a potential gain of +4% on today's $8.26. A consolidation phase looks the most probable path here.
In 2028, UPB is projected to trade between $6.72 and $12.44, averaging $8.83 — a potential gain of +7% from today's $8.26. That is up +3% on the projected 2027 average. Price action looks broadly range-bound.
Upstream Bio, Inc.'s 2029 outlook centres on $8.18, within a $6.07 to $11.89 range. That is -7% versus the projected 2028 average. That marks a -1% change versus current levels. A consolidation phase looks the most probable path here.
By 2030, UPB could reach as high as $12.80, with a base case around $8.58 and support toward $6.22 — roughly +4% from $8.26. Price action looks broadly range-bound.
Expect UPB to range from $6.79 to $14.60 through 2031. The $9.57 average target implies a +16% move from current prices. That is up +11% on the projected 2030 average. A consolidation phase looks the most probable path here.
The UPB price prediction for 2032 points to an average of $10.59 (low $7.38, high $16.49) — a potential gain of +28% on today's $8.26. Momentum favours further upside here.
In 2033, UPB is projected to trade between $8.08 and $18.75, averaging $11.82 — a potential gain of +43% from today's $8.26. That is up +12% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Upstream Bio, Inc.'s 2034 outlook centres on $12.25, within a $8.23 to $19.77 range. That is up +4% on the projected 2033 average. That marks a +48% change versus current levels. Momentum favours further upside here.
By 2035, UPB could reach as high as $20.35, with a base case around $12.42 and support toward $8.20 — roughly +50% from $8.26. Buyers look set to stay in control over this stretch.
Expect UPB to range from $10.48 to $30.00 through 2040. The $17.14 average target implies a +107% move from current prices. That is up +38% on the projected 2035 average. Momentum favours further upside here.
The UPB price prediction for 2050 points to an average of $26.28 (low $14.05, high $50.63) — a potential gain of +218% on today's $8.26. Buyers look set to stay in control over this stretch.
Investing $1,000 in UPB today (≈ 121.065375 UPB) could be worth
$3,182.09
+$2,182.09 (+218%) by 2050 · US Dollar
Based on the average projected UPB price of $26.28 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in UPBwould be worth at today's price.
$1,000 invested in UPB on May 27, 2025 (≈ 103.950105 UPB) would be worth
$858.63
-$141.37 (-14.1%) today · 0.86× · US Dollar
Based on a UPB entry price of $9.62 vs. today's $8.26.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $8.41 | $982.16 | -1.8% |
| 1 month ago | $9.29 | $889.13 | -11.1% |
| 3 months ago | $7.9 | $1,045.57 | +4.6% |
| 6 months ago | $28.6 | $288.81 | -71.1% |
| 1 year ago | $9.62 | $858.63 | -14.1% |
| All time (1.6y) ago | $22 | $375.45 | -62.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our UPB forecast.
Our base-case forecast reaches $17.00 around 2040.
Implied market cap at $17.00: $925.14M
The multi-year forecast shifts from neutral to bullish starting in 2032, with the 2032 average price at $10.47 and a 25.1% ROI. The trajectory continues to improve in the following years, with 2033 averaging $11.85 and a max of $19.08, ROI 41.6%. In 2034 the average is $12.32 with a max of $20.18, ROI 47.1%; 2035 shows $12.26 average and $20.42 max, ROI 46.5%.
By 2040 the forecast envisions a strong upturn—average $17.04, max $30.38, ROI 103.5%. In 2050 the average climbs to $25.76 with a max of $50.72 and ROI 207.8%.
These are estimates of price paths and are not guarantees; the near-term path remains sensitive to volatility, while the longer horizon shows substantial upside potential according to the projected min/avg/max values and NI-based ROIs.
Tap a question to reveal the answer.
In 2030 the forecast shows a min of $6.14, an average of $8.57, and a max of $12.94, with an ROI of 2.4%.
The outlook shows neutral sentiment through 2031 and bullish momentum starting in 2032, with the average price rising from $10.47 in 2032 to $25.76 in 2050 and ROIs reaching 25.1% in 2032 and up to 207.8% by 2050. These are estimates, not guarantees.
Yes. The forecast max reaches $20.18 in 2034 and $20.42 in 2035.
The 2040 forecast shows an average price of $17.04, a min of $10.18, a max of $30.38, and an ROI of 103.5%.
For 2050 the forecast shows an average of $25.76, a min of $13.30, a max of $50.72, and an ROI of 207.8%.
Upstream Bio, Inc. Community Discussion
0Share your Upstream Bio, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.